What are the most common peptide side effects?

For the growth-hormone-axis peptides (sermorelin, tesamorelin, CJC-1295/Ipamorelin), the documented effects include fluid retention, joint pain, injection-site reactions, and insulin resistance or glucose intolerance at higher doses. For most research peptides like BPC-157 and TB-500, there is essentially no human side-effect data — which means unknown risk, not proven safety.

Does BPC-157 have side effects?

There is no published human safety data for BPC-157, so its real-world side-effect profile is unknown. Because it acts on growth-factor and blood-vessel pathways, there is a theoretical concern about promoting tumor growth, but this has not been studied in humans. The practical risk is compounded by gray-market vials of unverified dose and purity.

Verified July 2026 · Cited to primary sources

Peptide side effects

Q: Can peptides cause cancer?

No peptide here has been shown to cause cancer in humans, but several carry a theoretical concern. Growth-hormone-axis peptides raise IGF-1, and BPC-157 and TB-500 promote angiogenesis (new blood-vessel growth) — mechanisms that could, in theory, support tumor growth. Epitalon's telomerase claims raise a similar theoretical flag. None of this is established; it is a reason for medical supervision, not a proven effect.

Q: Which peptides are banned in sport?

Several. BPC-157 is on the WADA Prohibited List under S0 (non-approved substances). The growth-hormone-axis peptides — sermorelin, tesamorelin, CJC-1295, Ipamorelin, and TB-500 — are prohibited under S2 (peptide hormones and growth factors). Tested athletes should treat these as bannable at all times.

Side effects depend on the peptide. The 3 best-studied growth-hormone-axis peptides can cause fluid retention, joint pain, and insulin resistance. For most research peptides, honest human side-effect data barely exists — which is its own kind of risk.

What are the side effects of peptides?

There is no single side-effect profile, because peptides work through completely different mechanisms. The most useful way to think about it is in two buckets: peptides with enough human data to know what they do (a short list), and peptides where the honest answer is “we don't know” (most of them). Both buckets carry risk — one documented, one unmeasured.

What are the side effects of growth-hormone-axis peptides?

These are the best-characterized peptides in this space, so their side effects are the best documented. Because they raise growth hormone and IGF-1, they share a family of “GH-excess” effects:

Fluid retention and swelling (edema)
Joint pain and, at higher doses, carpal-tunnel-type symptoms
Insulin resistance / glucose intolerance
Injection-site reactions
Elevated IGF-1, which carries a theoretical long-term cancer concern

Applies to Sermorelin, Tesamorelin, CJC-1295 / Ipamorelin. Sermorelin and tesamorelin are the best-tolerated of these because they have real approval-era human data; CJC-1295/Ipamorelin's marketed benefits are not backed by outcome trials.

Do BPC-157 and TB-500 have side effects?

Honestly: nobody knows, and that is the point. The famous recovery peptides have no published human safety trials, so their real-world side-effect profile is unmeasured. What exists is a theoretical concern — both promote angiogenesis (new blood-vessel growth), a mechanism that could in principle support tumor growth — plus the very real, non-theoretical risk of injecting a gray-market vial whose dose and purity can't be verified. “No reported side effects” in forum posts is not the same as “safe.”

The same “no human safety data” caveat applies to the other Grade-D peptides on the FDA docket: BPC-157, TB-500, KPV, MOTS-c, Epitalon.

Can peptides cause cancer?

No peptide here has been shown to cause cancer in humans — but several carry a theoretical concern worth understanding. Growth-hormone-axis peptides raise IGF-1; BPC-157 and TB-500 drive new blood-vessel growth; Epitalon is marketed on telomerase activation. Each of these mechanisms could, in theory, help existing abnormal cells grow. This is unproven and a reason for medical supervision and screening — not evidence that peptides cause cancer. FDA-approved GH-axis peptides are specifically contraindicated in active malignancy for this reason.

Which peptides are banned in sport?

If you are a tested athlete, treat these as off-limits. BPC-157 is prohibited under WADA category S0 (non-approved substances), banned at all times. The growth-hormone-axis and growth-factor peptides — sermorelin, tesamorelin, CJC-1295, Ipamorelin, and TB-500 — are prohibited under S2. A peptide being banned in sport is also a useful signal that it has a real physiological effect worth taking seriously.

What's the safest way to reduce peptide side effects?

The single biggest risk reducer is not a dosing trick — it is supervised access. A licensed clinician can screen for contraindications (like active cancer or uncontrolled diabetes), order baseline bloodwork, and prescribe a peptide dispensed by a regulated pharmacy at a verified dose. That removes the largest variable: a gray-market vial that isn't what the label says. See are peptides safe? for the supply-quality evidence, and are peptides legal? for which peptides even have a supervised route today. We do not provide dosing guidance — that is a conversation for your clinician.